Electrodes for electrical stimulation to treat cancer

Patent metadata

Field	Value
Publication number	US-11850422-B2
Application number	US-202016855433-A
Country	US
Kind code	B2
Filing date	Apr 22, 2020
Priority date	Apr 23, 2019
Publication date	Dec 26, 2023
Grant date	Dec 26, 2023

Abstract

Embodiments herein relate to medical devices and methods for using the same to treat cancerous tumors within a bodily tissue. A medical device system is included having an electric field generating circuit and control circuitry configured to control delivery of the one or more electric fields from the electric field generating circuit to the site of the cancerous tissue. An implantable lead is included having a lead body including a first electrical conductor disposed within the lead body, and a first electrode coupled to the lead body, the first electrode in electrical communication with the first electrical conductor, wherein the first electrical conductor forms part of an electrical circuit by which the electric fields from the electric field generating circuit are delivered to the site of the cancerous tissue, and the first electrode can include a conductive coil filar disposed around the lead body. Other embodiments are also included herein.

First claim

The invention claimed is:

1. A medical device system for treating a cancerous tissue, comprising:
an implantable medical device comprising:
an electric field generating circuit configured to generate one or more electric fields at or near a site of the cancerous tissue;
control circuitry in communication with the electric field generating circuit, the control circuitry configured to control delivery of the one or more electric fields from the electric field generating circuit to the site of the cancerous tissue;

wherein the control circuitry causes the electric field generating circuit to generate the one or more electric fields at frequencies selected from a range of between 10 kHz to 1 MHz using currents ranging from 1 mAmp to 1000 mAmp; and
an implantable lead comprising:
a lead body comprising a proximal end and a distal end, the lead body comprising a first electrical conductor disposed within the lead body; and
a first electrode coupled to the lead body, the first electrode in electrical communication with the first electrical conductor, wherein the first electrical conductor forms part of an electrical circuit by which the electric fields from the electric field generating circuit are delivered to the site of the cancerous tissue; and
a stent coupled to the lead body at a distal portion thereof;
wherein the stent comprises a stent frame formed of a bioerodible material.

2. The medical device system of claim 1 , wherein the stent frame serves as the first electrode.

3. The medical device system of claim 1 , wherein the first electrode is disposed on an outside surface of the stent.

4. The medical device system of claim 1 , wherein the stent comprises a stent frame formed of an electrically conductive material, wherein the stent frame is coated with a conductive fluid or gel.

5. The medical device system of claim 1 , wherein the stent is a rigid stent that does not expand or contract.

6. The medical device system of claim 1 , wherein the bioerodible material comprises a bioerodible metal.

7. A medical device system for treating a cancerous tissue, comprising:
an implantable medical device comprising:
an electric field generating circuit configured to generate one or more electric fields at or near a site of the cancerous tissue;
control circuitry in communication with the electric field generating circuit, the control circuitry configured to control delivery of the one or more electric fields from the electric field generating circuit to the site of the cancerous tissue;

wherein the control circuitry causes the electric field generating circuit to generate the one or more electric fields at frequencies selected from a range of between 10 kHz to 1 MHz using currents ranging from 1 mAmp to 1000 mAmp; and
an implantable lead comprising:
a lead body comprising a proximal end and a distal end, the lead body comprising a first electrical conductor disposed within the lead body; and
a first electrode coupled to the lead body, the first electrode in electrical communication with the first electrical conductor, wherein the first electrical conductor forms part of an electrical circuit by which the electric fields from the electric field generating circuit are delivered to the site of the cancerous tissue; and
a stent coupled to the lead body at a distal portion thereof;
wherein the stent comprises a stent frame formed of an electrically conductive bioerodible material;
wherein the stent frame is coated with a conductive gel.

8. The medical device system of claim 7 , wherein the stent frame serves as the first electrode.

9. The medical device system of claim 7 , wherein the first electrode is disposed on an outside surface of the stent.

10. The medical device system of claim 7 , wherein the stent is a rigid stent that does not expand or contract.

11. The medical device system of claim 7 , wherein the conductive gel comprises a chemotherapeutic agent.

12. The medical device system of claim 6 , wherein the bioerodible metal is magnesium alloy.

Assignees

• Boston Scient Scimed Inc

Inventors

• Schmidt Brian L
• Arnholt Devon N
• Maile Keith R
• Gruba Sarah Melissa
• Linder William J

Classifications

• A61N1/36002 Primary

  Cancer treatment, e.g. tumour · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61N1/05

  for implantation or insertion into the body, e.g. heart electrode (A61N1/06 takes precedence) · CPC title

• A61N1/08

  Arrangements or circuits for monitoring, protecting, controlling or indicating {(for external stimulators A61N1/3603; for implantable neurostimulators A61N1/36128; for heart stimulators A61N1/37; for defibrillators A61N1/3925)} · CPC title

• A61N1/06 Primary

  for high-frequency therapy · CPC title